A5085511052- Lung Cancer Treatments and Mutations
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Immunotherapy and Biomarkers
- Sunflower and Safflower Cultivation
- Economic and Financial Impacts of Cancer
- Statistical Methods in Clinical Trials
- Pharmaceutical Economics and Policy
- Traditional Chinese Medicine Analysis
- Pancreatic and Hepatic Oncology Research
- Chronic Disease Management Strategies
- Gastric Cancer Management and Outcomes
- Chronic Kidney Disease and Diabetes
- Health disparities and outcomes
- Protein Tyrosine Phosphatases
- Cytokine Signaling Pathways and Interactions
- Renal Diseases and Glomerulopathies
- Child Nutrition and Water Access
- Iron Metabolism and Disorders
- Healthcare Systems and Reforms
- Respiratory viral infections research
- Viral gastroenteritis research and epidemiology
- Tracheal and airway disorders
- Ginseng Biological Effects and Applications
- Tuberculosis Research and Epidemiology
- Esophageal Cancer Research and Treatment
China Pharmaceutical University
2019-2024
Examination of the prevalence and patterns multimorbidity among elderly in China.Cross-sectional study.More than 10 000 households 28 34 provinces mainland China.11 707 Chinese adults aged 60 over.Prevalence participants. Relative risks were calculated to estimate probability up 14 chronic conditions coexisting with each other. Observed-to-expected (O/E) ratios used analyse multimorbidity.Multimorbidity was present 43.6% respondents from sample population, women having greater compared men....
Objective: To assess the cost-effectiveness of atezolizumab in combination with carboplatin plus nab-paclitaxel-based chemotherapy versus alone for first-line treatment advanced non-squamous non-small cell lung cancer (NSCLC) from Chinese healthcare system perspective.Methods: A Markov model was developed based on IMpower130 clinical trial. Drug costs and health state utility were obtained literature. Outcomes included life-years (LYs), quality-adjusted (QALYs), lifetime costs, incremental...
As the first domestic PD-1 antibody approved for lung cancer in China, camrelizumab has exhibited proven effectiveness non-small-cell (NSCLC) patients. However, cost-effectiveness of this new regimen remains to be investigated.
Background Iruplinalkib is a second-generation anaplastic lymphoma kinase (ALK) tyrosine inhibitor (TKI) with efficacy in patients ALK-positive crizotinib-resistant advanced non-small cell lung cancer (NSCLC), which independently developed by Chinese pharmaceutical company. This study examined the cost-effectiveness of iruplinalkib versus alectinib healthcare setting. Methods A partitioned survival model was to project economic and health outcomes. Efficacy derived using unanchored...
To evaluate the cost-effectiveness of durvalumab in post-chemoradiotherapy patients with unresectable stage III NSCLC from Chinese healthcare system perspective.The study developed a five-health state Markov model to consolidation therapy based on PACIFIC clinical trial. Sensitivity and scenario analyses were performed uncertainty.Durvalumab provided an additional 1.22 quality-adjusted life-years (QALYs), incremental cost $24,397 compared no unselected patients. Durvalumab was cost-effective...
Sanqi Panax notoginseng injection and safflower yellow were Chinese traditional medicine injections for the treatment of cardiovascular diseases used to treat acute cerebral infarction patients in public hospital widely. The aim this study was compare analyze published reports efficacy safety infarction. cost-effectiveness these drug formulations also evaluated.China National Knowledge Infrastructure (CNKI), Wanfang, SinoMed, VIP, PubMed, Embase, Biomedical Literature (CBM) searched with...